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Abstract
Background:  The purpose of this study was to estimate the relative impact of changes in
demographics, stage at detection, treatment mix, and medical technology on 5-year survival among
older colorectal cancer (CRC) patients.
Methods: We selected older patients diagnosed with CRC between 1992 and 2000 from the
SEER-Medicare database and followed them through 2005. Trends in demographic characteristics,
stage at detection and initial treatment mix were evaluated descriptively. Separate multivariate
logistic regression models for colon (CC) and rectal cancer (RC) patients were estimated to isolate
the independent effects of these factors along with technological change (proxied by cohort year)
on 5-year survival.
Results: Our sample included 37,808 CC and 13,619 RC patients (combined mean ± SD age: 77.2
± 7.0 years; 55% female; 87% white). In recent years, more CC patients were diagnosed at Stage I
and fewer at Stages II and IV, and more RC patients were diagnosed at Stage I and fewer at Stages
II and III. CC and RC patients diagnosed in later years were slightly older with somewhat better
Charlson scores and were more likely to be female, from the Northeast, and from areas with
higher average education levels. Surgery alone was more common in later years for CC patients
while combined surgery, chemotherapy, and radiotherapy was more common for RC patients.
Between 1992 and 2000, 5-year observed survival improved from 43.0% to 46.3% for CC patients
and from 39.4% to 42.2% for RC patients. Multivariate logistic regressions indicate that patients
diagnosed in 2000 had significantly greater odds of 5-year survival than those diagnosed in 1992
(OR: 1.35 for CC, 1.38 for RC). Our decomposition suggests that early detection had little impact
on survival; rather, technological improvements (e.g., new medical technologies or more effective
use of existing technologies) and changing demographics were responsible for the largest share of
the change in 5-year survival in CC and RC between 1992 and 2000.
Conclusion: Technological advances and changes in patient demographics had the largest impact
on improved colorectal cancer survival during the study period.
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Background
Colorectal cancer (CRC) is the third-most common cancer
type in the United States and the third-leading cause of
cancer deaths among both men and women[1]. Almost
70% of CRC patients are diagnosed at age 65 years or
older. Currently, 5-year relative survival among US CRC
patients of all ages is estimated at around 65% and has
improved from 59% among patients diagnosed 20 years
ago[1]. The prognosis among older CRC patients is sub-
stantially worse, with 5-year survival estimated at 47%[2].
Early diagnosis is critical to the chances of survival in
CRC, with 5-year survival rates for patients of all ages
ranging from 95% for those diagnosed at Stage I to 7% for
those diagnosed at Stage IV[3].
Advances in screening technologies (such as flexible sig-
moidoscopy, FOBT, and colonoscopy), and an increase in
the proportion of the population undergoing regular
screening over the past decade may result in lower CRC
incidence and a shift toward detection at earlier stages[4].
Medicare's reimbursement policy was changed in 1998 to
provide coverage for screening colonoscopies for older
patients at increased colon cancer risk, and the policy was
expanded in 2001 to cover screening colonoscopies for all
Medicare enrollees[5]. Gross and colleagues evaluated
shifts in the stage distribution during the years surround-
ing these policy changes (1992–2002), finding that the
percentage of older patients diagnosed at an early stage
improved significantly[6]. Technologies such as com-
puted tomography also appear to have led to an improve-
ment in staging accuracy[7].
Most previous studies of survival in colorectal cancer have
used older and/or geographically limited data, have
focused only on certain stages, subsites, or subgroups in
the CRC population, have not focused on older patients,
or have used non-US data[8,9]. Additionally, there have
been few attempts to disentangle the complicated factors
contributing to improvements in survival. Aside from ear-
lier diagnosis, improvements in survival may also reflect a
myriad of other factors, such as changes in patient demo-
graphics or technological advances in the form of new
treatments or "know-how" (ie, more effective use of exist-
ing treatments). For example, from the late 1950s until
1996, fluorouracil (5-FU) was the only drug approved for
the treatment of colorectal cancer; however, since that
time, new targeted chemotherapies and improved surgical
techniques likely had positive influences on survival
rates[10]. Furthermore, advances in diagnostic techniques
that allow for better detection can lead to stage migration
and a misinterpretation of improved survival (sometimes
referred to as the Will Rogers effect)[11,12].
The objectives of this study were to investigate trends in 5-
year survival among older CRC patients and to disentan-
gle the relative influences of four key factors expected to
affect changes in survival over time: demographics, early
detection, treatment mix, and technological improve-
ments.
Methods
Data Source
This study used the linked Surveillance, Epidemiology,
and End Results (SEER)-Medicare database, a collabora-
tive effort of the National Cancer Institute, the SEER can-
cer registries, and the Centers for Medicare and Medicaid
Services (CMS). SEER is a surveillance system consisting of
population-based tumor registries designed to track inci-
dence and survival in the US. The registries routinely col-
lect information from multiple reporting sources (such as
hospitals, outpatient clinics, laboratories, private medical
practitioners, nursing and convalescent homes, hospices,
autopsy reports, and death certificates) about newly diag-
nosed cancer patients in geographically defined areas that
represent approximately 25% of the US population[13].
Complete details of the linkage of SEER and Medicare
data have been previously described elsewhere[14].
Briefly, the linked SEER-Medicare database used in our
study includes a SEER file of patients diagnosed with can-
cer within the geographic areas covered by SEER registries
between 1991 and 2000, as well as Medicare claims files
covering the period from 1991 through 2005. The SEER
files include demographics (eg, age, sex, race, date of
death), diagnosis information for up to 10 different inci-
dent cancer cases for each person (eg, date of cancer diag-
nosis, cancer subsite, cancer stage at diagnosis), and
indicators for chemotherapy and radiation treatment in
the first 4 months after diagnosis. The Medicare adminis-
trative claims files include monthly Medicare enrollment
data (eg, HMO enrollment, Part A and/or Part B eligibil-
ity), individual claims for inpatient and skilled nursing
facility (SNF) hospitalizations, outpatient hospital visits
and miscellaneous ambulatory services, Part B physician
services, home health agency services, and hospice serv-
ices, including dates of service, ICD-9-CM diagnosis and
procedure codes, DRG codes, HCPCS codes, primary
insurer payments, patient deductibles and copayments,
and Medicare payments for claims. Combining the SEER
registry data with the Medicare claims data offers the
opportunity to link service utilization over time to stage at
diagnosis, as well as the time from diagnosis to death.
Patient Selection and Follow-up
All patients aged 66 years and older with a new diagnosis
of malignant adenocarcinoma of the colon or rectum (ie,
presence of a SEER cancer site recode value between 15
and 27 and one of the following ICD-O-3 histology codes:
8140, 8210-11, 8220-21, 8260-63, 8470, 8480-81, or
8490) reported to a SEER registry between January 1, 1992BMC Cancer 2009, 9:227 http://www.biomedcentral.com/1471-2407/9/227
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and December 31, 2000 were identified for possible inclu-
sion in the CRC cohort. Only patients known to be diag-
nosed at Stages I-IV were included. To ensure that
complete data were available for evaluating comorbidities
and outcomes, patients were excluded if at any time in the
12-month period before the index date, or anytime after
the index date, they were enrolled in a Medicare HMO,
not eligible for both Medicare Part A and B benefits, or eli-
gible for benefits under the end stage renal disease pro-
gram. We also excluded patients who had claims in the
12-month pre-index period consistent with a history of
any other cancer, or were diagnosed with CRC at the time
of death or autopsy. Finally, since this analysis was con-
ducted as part of a study that evaluated costs among older
CRC patients and matched comparison patients[15], we
also excluded patients who could not be matched to an
appropriate comparator (less than 2% of the sample). The
index date for each patient was defined as the date of his
or her CRC diagnosis. Patients were followed for 5 years
after the index date or until death, whichever came first.
Statistical Analyses
Study patients were described in terms of baseline demo-
graphic and clinical characteristics including age, gender,
race, location of residence, cancer stage at diagnosis (Stage
I-IV), treatment type (surgery, chemotherapy, radiation,
and combinations thereof), and Deyo-Charlson comor-
bidity score[16] (calculated based on claims during the
12-month pre-index period). Treatments were identified
using SEER treatment variables as well as claims data in
the 3-month post-index period using ICD-9-CM diagnosis
and procedure codes, HCPCS/CPT codes, and revenue
center codes (Additional file 1: Table 1). Descriptive anal-
yses of trends in baseline and clinical characteristics and
5-year observed survival (evaluated in terms of the per-
centage of patients alive 5 years after CRC diagnosis) were
conducted.
Separate multivariate logistic regression models of 5-year
survival were estimated for CC and RC, controlling for
age, sex, race/ethnicity, region, urban/rural residence,
education (≤25% of residents in ZIP code with <12 years
of education vs. >25%), income (median household
income of ZIP code ≤$50,000 vs. >$50,000), stage at diag-
nosis (specified 2 ways: as individual dummy variables for
Stages II-IV and as one dummy variable for Stages II-IV
combined, both with Stages I as reference), treatment type
(surgery, chemotherapy, radiation, and combinations
thereof), and year of diagnosis. Year of diagnosis served as
a proxy for changes in medical technology in the regres-
sion model.
Results from the logistic regressions were used to model
the individual impact of 4 key factors (demographics,
early diagnosis, treatment mix, and technology) on
observed changes in 5-year survival in CC and RC between
1992 and 2000. We first used estimated coefficients from
the logistic regressions to predict 5-year survival in 1992
using average 1992 values for all variables in the regres-
sions. We then generated 4 hypothetical predicted values
of 5-year survival in 2000 by changing each of the factors
of interest in the model one at a time to their average 2000
value, keeping all other variables at their average 1992 val-
ues. The individual impact of each factor was obtained by
dividing the relevant hypothetical predicted survival for
2000 by the prediction for 1992. Summing the individual
effects yielded an estimate of the overall change in 5-year
survival from 1992 to 2000. For the decomposition anal-
ysis, we used results from the logistic regression in which
stage at diagnosis was specified as early vs. late (ie, Stage I
vs. Stages II-IV combined) because the low survival rate
among Stage IV patients led to underprediction using the
models with individual stage dummy variables.
All analyses were conducted separately for colon and rec-
tal cancer patients. All data analyses were conducted using
the Statistical Analysis System (SAS) software package,
version 9.1 (Cary, North Carolina, USA).
Results
Patient Characteristics
There were 124,280 patients in the dataset, of which
51,427 met all study inclusion criteria (37,808 CC
patients and 13,619 RC patients). Demographic and clin-
ical characteristics for study patients are presented in
Additional file 2: Table 2. The mean ± SD age was 77.2 ±
7.0 years and approximately 87% were white, with about
57% of CC patients and 50% of RC patients being female.
Approximately 25% of the overall CRC population was
diagnosed at Stage I, 32% at Stage II, 24% at Stage III, and
19% at Stage IV (Additional file 2: Table 2). RC patients
were more likely than were CC patients to be diagnosed at
Stages I or IV. In the overall CRC population, the mean ±
SD Charlson comorbidity score (not including cancer)
was approximately 1.9 ± 1.9. Common comorbidities
included chronic pulmonary/respiratory disease, conges-
tive heart failure, and diabetes without complications.
Baseline and demographic characteristics did not differ
substantially by year of diagnosis, although individual
years had some small differences in the Charlson score
(slightly declined over the study period), and the distribu-
tions of age, region, education levels, and treatment mix
(data not shown). CC and RC patients diagnosed in 2000
were about a year older on average, and were slightly more
likely to be female, from a zip code with a higher average
education level, and from the Northeast than were those
diagnosed in 1992. CC patients diagnosed in 2000 were
more likely to receive surgery only than those diagnosed
in 1992, and RC patients were more likely to receive sur-BMC Cancer 2009, 9:227 http://www.biomedcentral.com/1471-2407/9/227
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gery, chemotherapy, and radiotherapy. Figure 1 illustrates
trends in the distribution of stage at diagnosis by year of
diagnosis and cancer subsite. Comparing diagnosis years
1992 and 2000, the data show a trend toward more CC
patients diagnosed in Stage I and fewer in Stages II and IV.
For RC patients, we observed an increase over time in the
number of patients diagnosed at Stage I instead of Stages
II and III.
Trends in 5-year Survival
Comparing patients diagnosed in 1992 and 2000, overall
5-year survival improved by 7.7% (from 43.0% to 46.3%)
for CC patients and by 7.1% (from 39.4% to 42.2%) for
RC patients (Figure 2). The largest improvement for both
CC and RC patients was in Stage III (35.4% to 41.5% for
CC patients, 36.3% to 39.9% for RC patients), while Stage
I CC patients and Stage IV RC patients exhibited slight
declines in 5-year survival.
Predictors of 5-year Survival
Multivariate logistic regression results predicting 5-year
survival for CC and RC patients, along with correspond-
ing 95% confidence intervals and P values, are shown in
Additional file 3 Table 3. Among both CC and RC
patients, younger patients (66–74 and 75–84 yrs vs. 85+
yrs), women, and those in more educated ZIP codes had
significantly better odds of 5-year survival. Patients living
in metropolitan counties, those with lower incomes, and
those with higher Charlson scores had significantly worse
odds of surviving 5 years. Receiving any type of treatment
had a large and significant impact on 5-year survival, with
patients who received both surgery and chemotherapy
having the highest odds of survival in both cohorts.
Patients diagnosed in later stages had significantly and
progressively worse odds of 5-year survival than those
diagnosed at Stage I. Being diagnosed in a later year – our
proxy for changes in technology – was also associated
with significantly better odds of 5-year survival for both
CC and RC patients, with patients diagnosed in 2000
Stage distribution by year of diagnosis and cancer subsite Figure 1
Stage distribution by year of diagnosis and cancer subsite.
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between 1.3 and 1.4 times more likely than patients diag-
nosed in 1992 to survive 5 years, holding all other varia-
bles constant.
Decomposition of Changes in 5-year Survival
Figure 3 presents estimates of the individual impact of
changes in demographics, treatment mix, stage at diagno-
sis, and technology (year of diagnosis) on 5-year survival
from 1992 to 2000. Among CC patients, changing only
demographics between 1992 and 2000 (and leaving all
other variables at their 1992 values) resulted in an esti-
mated 9.9% reduction in predicted 5-year survival. In
other words, if patients diagnosed with CRC in 2000 had
the same demographic characteristics as their counter-
parts in 1992, their 5-year survival would have been lower
by 9.9%. Changing only the treatment mix yielded no
change in survival, while changing only the stage distribu-
tion yielded a 2.7% increase. Finally, changing only the
year dummy, which is intended as a marker for improve-
ments in technology, to 2000 resulted in a 17.2%
increase, by far the largest impact among all factors stud-
ied.
Among RC patients, changing only demographics
between 1992 and 2000 resulted in an 11.4% reduction in
predicted 5-year survival. Changing only the treatment
mix yielded a 3.6% reduction, while changing only the
stage distribution resulted in a 4.3% increase. Finally,
changing only the marker for technology to 2000 led to
the highest predicted probability of 5-year survival, a
19.7% increase.
Summing the individual positive and negative impacts of
the 4 factors of interest yielded estimated net increases in
predicted 5-year survival during the study period of 10.0%
in CC and 9.0% in RC. These estimated net increases are
somewhat higher than the observed increases in 5-year
survival in CC and RC during the study period (ie, 7.7%
and 7.1%, respectively), likely resulting from imprecision
in the prediction model and additional unmeasured influ-
Five-year survival, by cancer subsite and year of diagnosis Figure 2
Five-year survival, by cancer subsite and year of diagnosis.
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ences that had a small net negative impact on 5-year sur-
vival during the study period.
Discussion
This study evaluated factors affecting the change in 5-year
survival among Medicare beneficiaries diagnosed with CC
and RC between 1992 and 2000. We found that patients
diagnosed in 2000 were about a year older on average,
with slightly lower Charlson scores, and were more likely
to be female than those diagnosed in 1992. CC and RC
patients diagnosed in 2000 were more likely to receive
surgery only and surgery, chemotherapy and radiother-
apy, respectively, than were patients diagnosed in 1992.
We found that there have been considerable changes in
stage distribution between 1992 and 2000, and that unad-
justed 5-year survival improved by 7.7% (from 43.0% to
46.3%) for CC patients and by 7.1% (from 39.4% to
42.2%) for RC patients. As a comparison, unadjusted 5-
year survival for patients in our larger study, who were
matched to our CRC patients on age and gender, was
70.9% (unpublished authors' analyses).
Controlling for year of diagnosis and treatment mix, being
diagnosed at later stages was shown to have a substantial
negative impact on 5-year survival, as we would expect.
Similarly, controlling for stage at diagnosis, patients diag-
nosed in later years (1996–2000) had significantly better
survival odds than did patients diagnosed in 1992. In
decomposing the effects of demographics, treatment mix,
stage at diagnosis and technological change, we found
that changes in demographics between 1992 and 2000
had a large negative effect on 5-year survival, while year of
diagnosis, which we hypothesized as a marker for techno-
logical improvements, had the largest positive effect on 5-
year survival. These results suggest that, despite the
amount of effort that has gone into screening and colon-
oscopies, changes in stage distribution have contributed
only a small amount to improvements in 5-year survival.
This may be due, in part, to a possible bias caused by
improved staging. Whereas screening and colonoscopies
may have led to finding cancers earlier, improvements in
staging accuracy may have contributed to a stage migra-
tion effect[11,12].
Estimated changes in 5-year survival from 1992 to 2000 resulting from changes in demographics, treatment, stage distribution  and technology Figure 3
Estimated changes in 5-year survival from 1992 to 2000 resulting from changes in demographics, treatment, 
stage distribution and technology.
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Our study contributes to the existing literature on survival
in colorectal cancer by focusing explicitly on older
patients (the primary age group affected by this cancer),
and by evaluating the latest available data, thus reflecting
some of the recent changes in treatment patterns and
detection for CRC. In addition, to our knowledge, ours is
the first study that has attempted to disentangle the effects
of earlier detection, demographics, treatment mix, and
improvements in technology on 5-year survival in CRC
patients using logistic regression techniques.
Comparisons with Other Literature
Despite some methodological differences, our findings
are consistent with previous research on changes in stage
distribution and survival in CRC. Recently, Gross et al
used 11 years of SEER-Medicare data (1992–2002) to
evaluate changes in the distribution of stage at diagnosis
among colon cancer patients[6]. They compared 3 time
periods: before the first change in Medicare's reimburse-
ment policy (1992–1997), between the first and second
changes (1998–June 2001), and after the second change
(July 2001–2002). They showed that the proportion of
CC patients diagnosed at an early stage increased from
22.5% in period 1 to 25.5% in period 2 and 26.3% in
period 3 (all significant increases), and our results were
nearly identical.
Three previous studies have analyzed increases in US
colorectal cancer survival rates over time, all of which
examined a wider range of ages than our study. Jemal et
al[17] compared 5-year relative survival rates from the
mid-1970s to 1995–2000 and found that colorectal can-
cer had the second-highest improvement in survival rates
of all cancer types in that time period. They found that 5-
year survival increased among men from 50% to 64% and
among women from 52% to 63%. Brenner et al[8] con-
ducted a period analysis of SEER data on 5- and 10-year
relative survival and found that both colon and rectal can-
cer patients had improved survival from 1998 to 2003.
They found that for colon cancer patients, 5-year relative
survival improved from 63% to 66% and 10-year survival
improved from 57% to 62%, and for rectal cancer
patients, 5-year relative survival improved from 64% to
67% and 10-year survival improved from 56% to 60%.
Finally, Clegg and colleagues[18] generated Kaplan-Meier
estimates from SEER data and determined that relative
survival had significantly improved from 1988 to 1997.
Using similar data (1986–1997 SEER data), another study
found that there were no significant improvements in 5-
year relative survival[19]. However, this study split the
years of interest into 4 groups, concluding that there was
no significant improvement in survival from 1986–1988
to 1995–1997.
Our results differ from previous studies for several rea-
sons: 1) our population was limited to older patients; 2)
we excluded patients who were enrolled in an HMO, who
may have been healthier or had other characteristics that
differed from the patients in our sample; and 3) we meas-
ured observed, rather than relative, survival. Observed sur-
vival takes all causes of death into account, whereas
relative survival – the ratio of observed survival to
expected survival in a comparable group of cancer-free
individuals – is substantially higher than observed sur-
vival in older CRC patients[20]. Using cause-specific sur-
vival to estimate relative survival requires that the
information on cause of death be reliably coded. Even
when cause of death is available to a cancer registry via the
patient's death certificate, the information is often diffi-
cult to interpret. For example, Welch et al[21] studied
deaths among cancer patients that occurred within 1
month of diagnosis and found that 41% of deaths were
not attributed to the coded cancer.
Few previous studies have attempted to isolate the impact
of individual influences on survival in CRC, with most
analyzing survival using joinpoint analysis and annual
percentage changes instead[3,8]. However, in a recent
analysis, Sun and colleagues evaluated the impact of treat-
ment and stage distribution on survival for multiple can-
cers using SEER data[22]. They found that advances in
treatment accounted for the majority of observed changes
in survival (78% for all cancers examined) between 1980
and 2000. Since these researchers did not distinguish
between treatment mix and technological advances in
treatment and did not account for the influence of demo-
graphics, it is not possible to compare our results directly.
However, their findings are consistent with ours in sug-
gesting that advances in treatment (ie, technology) had
the greatest impact on changes in survival over time.
Limitations
This study is subject to certain limitations that are com-
mon to all studies that rely on retrospective claims data,
such as potential coding errors and incomplete data[23].
Our use of the SEER-Medicare database, which includes
complete claims only for Medicare-eligible patients aged
65 years and older, introduces additional limita-
tions[24,25]. While older patients comprise the vast
majority of patients with CRC, this sample is not repre-
sentative of all US patients, particularly those with other
forms of health insurance (eg, managed care, private pay).
Despite its limitations, SEER-Medicare data have been
used in numerous published studies of colon cancer, as
well as cancers of the breast, prostate, and lung, among
others[26]. In addition, this study observed improve-
ments in survival among CRC patients that may not be
independent of improved survival for the general popula-
tion. This study relied on year dummy variables to meas-BMC Cancer 2009, 9:227 http://www.biomedcentral.com/1471-2407/9/227
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ure changes over time, which required the assumption
that all determinants of survival were included and accu-
rately measured in our specification.
Until recently, a combination of fluorouracil (5-FU) and
leucovorin was the standard of care for CRC; numerous
other drugs have been approved for use in CRC patients
since 2004, including oxaliplatin, bevacizumab, cetuxi-
mab, and panitumumab[27]. Because our study period
ended in 2005, the influence of these new treatments on
survival could not be measured. Future researchers will
have the ability to use data collected since 2004, which
will likely show greater changes in survival attributable to
changes in treatment mix. Future researchers will also be
able to use the methods we have described in this study to
investigate whether changes in survival among cancer
patients or other groups of patients may be attributable to
changes in demographics, stage distribution, treatment
mix, or technology.
Conclusion
Five-year CRC survival rates improved between 1992 and
2000. Changes in demographic characteristics of patients
diagnosed with CRC worked against their survival, while
technological advances have made the largest contribu-
tion towards improvement in survival during the study
period. Our findings will be useful in shaping policy dis-
cussions regarding CRC treatment and screening, and our
novel methods may enable future researchers to disentan-
gle the various complicated influences on survival.
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